



The influence of medication on erectile function

W Meinhardt¹, RF Kropman², P Vermeij³, AAB Lycklama à Nijeholt⁴ and J Zwartendijk⁴

¹Department of Urology, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands; ²Department of Urology, Leyenburg Hospital, Leyweg 275, 2545 CH The Hague, The Netherlands; ³Pharmacy; and ⁴Department of Urology, Leiden University Hospital, P.O. Box 9600, 2300 RC Leiden, The Netherlands

Keywords: impotence; side-effect; antipsychotic; antihypertensive; physiology; erectile function

Introduction

Several physiological mechanisms are involved in erectile function. A negative influence of prescription-drugs on these mechanisms will not always come to the attention of the clinician, whereas a drug causing priapism will rarely escape the attention.

When erectile function is influenced in a negative way compensation may occur. For example, age-related penile sensory disorders may be compensated for by extra stimulation.¹ Diminished influx of blood will lead to a slower onset of the erection, but may be accepted. A mild 'venous leak' can be compensated by extra inflow of blood² and the suboptimal rigidity may be accepted. Therefore a negative influence of medication on the erectile function will not always lead to a complaint.

The problems themselves for which drugs are prescribed, such as cardiovascular disease, psychosis, depression, diabetes mellitus may have a negative effect on sexual and erectile function. In this situation the already compromised system is more vulnerable to adverse effects of medication. Erroneously the erectile dysfunction may be attributed to the disease, instead of the medication. In geriatric patients, who often use several medicines at the same time, the issue is even further complicated.³

Many patients will not discuss their sexual problems when not invited to do so. In clinical practice all this will result in an underestimation of the drug factor in impotence. It has been estimated that the drug factor plays a role in 25% of patients seeking advice for erectile dysfunction.⁴ Patient compliance concerning correct medication usage, is, among other things, dependent on side-effects. In a large follow-up program 8.3% of the male patients

stopped their antihypertensive treatment over a five year period, because of side-effects on sexual function.⁵ In the drug registration procedures sexual function is not a major issue. This means that knowledge of the problem is mainly dependent on case reports and the lists from side effect registries.⁶⁻⁸

Another way of looking at the problem is combining available data on mechanisms of action of drugs with the knowledge of the physiological mechanisms involved in erectile function. The advantage of this approach is that remedies may evolve from it.

In this paper we will discuss the subject in the following order:

Physiology:

- Penile erection
- Control mechanisms
 - hormonal system
 - central nervous system
 - peripheral nervous system
- Cavernous tissue function

Prescription drugs:

- psychotropic drugs
- cardiovascular drugs
- miscellaneous drugs
- drugs to treat erectile disorders

Guidelines for clinical practice

Penile erection

An extensive review on the physiology of penile erection has been published by Andersson.⁹ The initiation of an erection is a neurogenic event. The impulses may originate from the brain (as in REM sleep erections) or derive from sacral reflexes (as in some paraplegic patients). In normal circumstances it will be a combination of both. Dilatation of the arteria cavernosa and the helicine arteries is con-

Correspondence: Dr W Meinhardt.

Received 25 July 1996; accepted 21 October 1996

trolled by the well described neural regulation mechanisms. This is however not sufficient for the development of a rigid erection, since there are shortcuts to the venous channels and the resistance of the lacunar spaces in the corpora cavernosa depends on smooth muscle tone. Relaxation of the smooth muscle cells is necessary for the expansion of the corpora, this is initiated by parasympathetic impulses. Sympathetic tone needs to be reduced, since this causes contraction of the smooth muscle cells. The search for non cholinergic, non adrenergic (NANC) transmission of the impulses of the nervous system to the smooth muscle cells has drawn attention to nitric oxide (NO) as an initiator of a cascade of chemical events that results in relaxation of all the smooth muscle cells of the corpora.^{10,11} After the first impulses, the scarcely innervated network of endothelial cells and smooth muscle cells take care of their own coordination in order to relax all at the same time. This is accomplished through tight junctions and gap junctions. Free inflow of blood is allowed in the lacunae, finally resulting in such a tumescence that outflow of blood will be stopped by compression of the venous channels between the distended corporal tissue and the tunica albuginea. This leads to rigidity of the penis that may be further enhanced by contractions of pelvic floor muscles, compressing the crurae of the corpora cavernosa and building a pressure that is higher than the systolic blood pressure.¹² Inflow of blood to the corpora cavernosa is minimal at that point. The erection comes to an end by renewed contraction of the smooth muscle cells, initiated by sympathetic impulses and by the production of substances such as endothelin-1, prostaglandin F_{2α} and thromboxane A₂ by the endothelial cells.^{9,13} This will allow venous outflow by decompression of the subtunical venous plexus.

Control mechanisms

Several control mechanisms play a role in sexual behavior and erectile function. Many have effects on the central nervous system as well as on the cardiovascular system. There is an analogy in the responses of blood vessels to these regulation mechanisms and the responses of the tissue in the corpora cavernosa.

Hormonal system

The exact role of testosterone on erectile function is not well defined. The negative influence of castration on libido is regularly seen in clinical practice.

The negative effect of castration on erectile function may be secondary to this. Erections during REM sleep are inhibited by castration, suggesting an influence on the central nervous system.^{14,15}

The adult corpus cavernosum hardly has any receptors for testosterone, while in children testosterone induces growth of the penis, rather than erections.¹⁶ It has been shown that the hormonal manipulation preceding gender reassignment (pharmacological castration) lowers the amount of nitric oxide synthase (NOS) in the corpus cavernosum tissue.¹⁷ In a rat model nitric oxide mediated erectile activity was a testosterone dependent event, while in another rat model it was shown that dihydrotestosterone levels positively correlate with the amount of NOS in the corpus cavernosum.^{18,19} However, after castration the local mechanisms leading to penile smooth muscle relaxation are not impaired, possibly since compensation occurs by lowering of the sympathetic tone.²⁰

The testosterone serum level is mainly determined by the epiphyse/pituitary/testes feedback system. Estrogens and steroid-antiandrogens influence the testosterone serum level via this system. High prolactin levels also lower the testosterone production. Hyperprolactinaemia may be drug induced. Cimetidine, estrogens, metoclopramide, α-methyl dopa, morphine and the phenothiazines are known for this. The elevation of prolactin serum levels is usually mild and not accompanied by a decrease in serum testosterone levels. In absence of a low testosterone serum level the relation of hyperprolactinaemia and impotence is unclear and withdrawal of the culprit drug maybe disappointing because of other organic factors determining the erectile dysfunction.²¹

Some drugs have an unexpected anti-androgen effect such as H₂-antagonists and some antifungal drugs. Effects on the testosterone levels have been described of beta blockers, spironolactone and digoxin, the practical value of these reports is unclear.²²⁻²⁴

Central nervous system

Emotional and cognitive factors influencing sexual behavior and erectile function are beyond the scope of this review. Several parts of the brain are involved in sexual function and already on this central level integration with autonomous regulation of other body functions is present. The brain may inhibit or facilitate the spinal mechanisms leading to an erection. Among others, the hypothalamic and limbic pathways are intensively studied. The medial preoptic hypothalamic area, in contact with the paraventricular nucleus of the hypothalamus is important for autonomic and neuroendocrine inte-

gration.⁹ Dopaminergic systems and serotonergic systems play a major role in sexual behavior and erectile function.²⁵ For several psychopharmaca these systems are the specific target.²⁶ Apomorphine, a central dopamine agonist, is effective in enhancing sexual behavior in the animal model as well as in humans.²⁷ For this effect testosterone needs to be present.²⁸ There is evidence that this effect is also dependent on oxytocine release.⁹ Dopamine also has cardiovascular effects, mediated by several distinct types of receptors that vary in their affinity. In low concentrations dopamine acts on vascular D1 receptors, leading to vasodilatation. In somewhat higher doses it activates the beta-1 adrenoceptors, whereas at high concentrations vasoconstriction is effectuated via activation of vascular alpha-1 adrenoceptors.²⁹

Of the serotonergic system mainly the 5-HT_{1A}, 5-HT_{1C} and the 5-HT₂ receptor subtypes play a facilitory role in human sexual behavior and antagonists have a negative influence.^{25,26} On this level the explanation may be found why such a marked difference was shown between the effectiveness of several anti-serotonergic agents in impotence treatment.³⁰

For a stimulatory effect of 5-HT_{1A} agonists testosterone needs to be present.³¹ Cardiovascular effects of serotonin may be constricting or dilating, depending on the type of receptor activated, while serotonin also influences the release of noradrenaline from adrenergic nerves and stimulates endothelial cells to release prostaglandins and NO.²⁹

Noradrenergic neurons also play a role in the central regulation of sexual function.⁹ Methyldopa, an older antihypertensive drug, may so be responsible for erectile dysfunction.⁶ The selective alpha-2 adrenoceptor antagonist yohimbine may improve libido and its main effect in vivo is probably on the central nervous system.³² Of the central neurotransmitters oxytocin, ACTH and related peptides, prolactin, gamma-aminobutyric acid and endorphins are all implicated in the regulation of sexual behaviour and erectile function.⁹ Stress may influence the production of endogenous opioids which has reflections on the hypothalamic-pituitary-luteinizing hormone axis.³³

Peripheral nervous system

Somatic pathways are important for sensitivity of the penile skin and the contraction of the pelvic floor muscles. The autonomic nervous system is essential for erectile function. The pharmacology of the autonomic system has been extensively studied. At the ganglionic level (the nicotinic acetylcholine receptor) the system will respond to drugs in the usual way. At this site integration of parasympathetic and sympathetic impulses takes place and the

mechanisms of homotropic and heterotropic interaction can be influenced by drugs. The pelvic ganglions are also the site where neuromodulation takes place by various endogenous substances (serotonin, adenosine, histamine, enkephalin and dopamine) at their specific receptors.²⁹ At the peripheral level the existence of different receptor subtypes and the relative affinity of drugs to these receptors makes prediction of the resulting effect of drugs on the corporal smooth muscle tissue complicated.

Sympathetic nervous system

The smooth muscle has a resting tone that is mainly governed by tonic alpha receptor stimulation.³⁴ Reduction of sympathetic tone is important to initiate a reaction, but does not result in penile erection. Bilateral sympathectomy does not cause priapism. Psychogenic inhibition of erections is mediated by the sympatic nerves and by circulating catecholamines.³⁵ Ejaculation is controlled by the sympathetic nervous system. Thereafter detumescence is initiated by the sympathetic pathway, inducing contraction of the smooth muscles of the corpora cavernosa and so allowing outflow of blood. Reviewing the subject of receptors, Andersson concludes that for the cavernosal tissue alpha-1 adrenoceptors predominate functionally, alpha-1A and alpha-1C being more numerous than alpha-1B adrenoceptors.⁹ Alpha-2 adrenoceptors predominate in the cavernous artery.⁹ The beta-2 adrenoceptors, although present, are not supposed to be functionally important.³⁶ For impotence treatment with drugs applied intracavernously (i.c.) the alpha adrenoceptors are an important target.³⁷ Blockade of alpha adrenoceptors by medication may cause priapism.³⁸

Parasympathetic nervous system

Transection of the nervi erigenti leads to impotence because the induction of smooth muscle relaxation, followed by high inflow of blood, is a parasympathic event.³⁹ The parasympathetic impulse however is not only the result of direct cholinergic transmission by acetylcholine to muscarine receptors on the smooth muscle cells in the corpora cavernosa. It is supposed to have its effect by inhibiting the release of noradrenaline from sympathetic nerve endings and by the release of Non Cholinergic Non Adrenergic (NANC) transmitters from the parasympathetic nerve endings and from the endothelial cells.^{9,40} NO is one of the main NANC transmitters.^{10,11}



Cavernous tissue function

From his experience with i.c. injection therapy Goldstein⁴¹ formulated a cascade theory, in which he combines pharmacologic events with physiology and anatomy. After an i.c. injection with vaso-active drugs relaxation on that site in the cavernous tissue leads to local increase of blood inflow. This is followed by activation of endothelium-mediated relaxation factors, the zone of muscle relaxation is enlarged, leading to local increase of blood inflow etc. If any part of the corpora cavernosa is not completely relaxed, venous return is not sufficiently stopped and rigidity is suboptimal or of short duration. This is the equivalent of the clinical concept of 'venous leakage' that may be quantified by cavernosometry.⁴² The pathways by which the smooth muscle cells communicate and the role of the endothelial cells of the corpora cavernosa are under investigation.

The smooth muscle cells are in contact with each other through gap junctions. In cavernous tissue they consist mainly of calcium and potassium channels.^{43,44,51} In this way integrated action is possible, since this allows for relatively unimpeded intercellular transit of current carrying ions and transit of small metabolites and second messengers as inositol triphosphate, cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). For more details we refer to excellent reviews on this matter from Andersson and Christ.^{9,45}

Several products of the nerve endings and the endothelial cells can initiate smooth muscle relaxation, such as NO, vasoactive intestinal peptide (VIP), neuropeptide Y, calcitonin gene related peptide, substance P, prostanoids.^{46,47} Especially NO has drawn much attention as an important regulator of smooth muscle tone in the corpora cavernosa.^{10,11} NO is produced by autonomic nerve endings and by endothelial cells from L-arginine and molecular O₂ by NO synthase (NOS). NOS is available in several isoforms and its production can be stimulated in several ways.⁴⁸ In chronic hypoxic states NO formation is reduced.⁴⁹

NO activates guanylate cyclase, the conversion of GTP to cGMP lowers the calcium concentration and leads to relaxation of the smooth muscle. In addition to the cGMP pathway, activation of NA/Ka-ATPase may also play a role in the relaxation of corpus cavernosum tissue by NO.⁵⁰ Cyclic nucleotide phosphodiesterases (PDE) are enzymes that hydrolyse cGMP and cAMP to monophosphates. PDE may be blocked by pharmacological agents, for example papaverine.^{51,52} Several PDE subtypes can be identified. In the corpora cavernosa PDE₅ is predominant and this subtype is blocked by sildenafil.^{53,54} These insights in the physiology of the corpus cavernosum have already led to new possibilities for i.c. injection

therapy, for example the use of the NO donors linsidomin and of calcitonin gene related peptide.^{55,56} The data from research of oral medication acting on these systems becomes available now.^{53,54,57}

Prescription drugs

Psychotropic drugs

Especially antipsychotic and antidepressant drugs are known for their side effects on erectile function.⁶⁻⁸ In clinical practice the patients in need of these drugs may not be ideal candidates to have their sexual performance evaluated. Much is known from animal studies. Side effects may be due to adrenergic, anticholinergic, dopaminergic or serotonergic effects.⁵⁸ Other psychotropic drugs such as benzodiazepines, are reported to cause impotence. Maybe this effect is simply the result of sedation.⁶ Unexplained is the finding that lithium when combined with benzodiazepines is associated with sexual dysfunction in almost half of the patients.⁵⁹

Antipsychotics and antidepressants have an effect on the dopaminergic and the serotonergic central nervous system that may be stimulating or inhibiting. The combination of stimulating central effects with peripheral alpha-blocking properties may induce priapism, because the alpha receptors in the cavernous tissue are important for contraction of smooth muscle cells and so the initiation of detumescence. The most reported antidepressant drug that causes priapism is trazodone.⁶⁰ This antidepressant drug has been applied i.c. and induced smooth muscle relaxation.⁶¹ It is also known for its ability to improve libido.^{62,63} Clomipramine, a tricyclic antidepressant that combines serotonin reuptake inhibitor properties with alpha blocking properties is more effective for treatment of premature ejaculation, than for treatment of erectile dysfunction.⁶⁴ Fluoxetine has been associated with erectile dysfunction as well as with the return of potency.^{8,65} More consistent is its postponing effect on the ejaculation.⁶⁶ When erectile dysfunction is caused by a tricyclic antidepressant drug it may be rational to try the patient on trazodone or fluoxetine instead.⁶⁷ However one must consider the possibility that erectile dysfunction might persist in the presence of an increased libido.

Of several antipsychotics the alpha-blocking properties are known, so in case of drug induced impotence one might consider an alternative drug with stronger alpha-blocking properties, a higher affinity for the alpha-1 receptor. The affinity for the alpha-1 receptor in decreasing order is: thioridazine,

levopromazine, clozapine, zuclopentixol, haloperidol, bromperidol, pimozone.⁶⁸ When the alpha-blocking properties induce priapism, an alternative antipsychotic must be used with a lower affinity to the receptor. The susceptibility of the patient may change with time and also co-medication with alpha-blocking properties must be considered. Recurrent priapism due to depot zuclopentixol has been reported.⁶⁹

Cardiovascular drugs

To initiate an erection a generous inflow of blood is needed. The classical combination of claudication intermittents and impotence, due to stenosis of central arteries is known as the Leriche syndrome. Arteriosclerosis is accompanied by degenerative changes in the corpus cavernosum.^{70,71} These changes make the veno-occlusive mechanism less effective. Dysfunction of the corpus cavernosum tissue is the main cause of 'venous leakage'.⁴² The combination of inflow reduction with a diminished possibility to trap the blood in the penis, is detrimental for erectile function.² The patient in need of cardiovascular drugs already has a vulnerable erectile function and they will be more susceptible for medication induced erectile dysfunction. In addition to this, many cardiovascular drugs have a direct influence on the autonomous innervation of the penis. Betablocking agents are known for their negative effects on erectile function. This may be due to their effect on the beta adrenoceptors in the corpora cavernosa, but these are underrepresented in the cavernous tissue (alpha receptors outnumber beta adrenoceptors 10–1).³⁶ Another explanation is a change in balance between alpha and beta sympathetic influence, resulting in insufficient antagonism of the alpha-1 vasoconstriction.⁷² When betablocking agents prescribed for high bloodpressure cause impotence, an alpha-blocking agent may be a good alternative. Even alphablocking agents have been implicated as the cause of erectile dysfunction.^{7,8} This may be due to the lowering of the bloodpressure as such.⁷³ Possibly making these patients more vulnerable for a steal phenomenon. Alphablocking agents have an effect on the ejaculation, they may delay ejaculation or cause a retrograde ejaculation and so give rise to secondary (psychogenic) erectile dysfunction. Alphablockers interfere with the sympathetic induced detumescence and may cause priapism.

Several vasodilators have a relaxing effect on the corporal tissue when applied intracavernously or even topically, but this effect is not obvious when these drugs are taken orally. Many vasodilators act upon the calcium and potassium channels. Calcium reentry blocking agents are considered safe treat-

ment as far as erectile function is concerned.⁷⁴ On cavernous smooth muscle they have a relaxing effect.⁷⁵ When injected i.c. they induce erections.⁷⁶ However they are reported as responsible for erectile dysfunction.^{7,8} This may be due to the drop in blood pressure, provoking a sympathetic nervous system response.⁷⁶ Potassium channel openers, with pinacidil as well studied example, do show an erectogenic effect when directly applied to the corporal tissue. But taken orally potassium channel openers are not suitable for impotence treatment because of insufficient tissue selectivity and the stimulation of the sympathetic nervous system.^{77–79} Minoxidil is an exception in this respect, being applied as ointment for induction of tumescence, while taken orally it has been reported to cause priapism.⁸⁰

The above mentioned mechanisms may play a role in impotence caused by ACE-antagonists. Since angiotensin converting enzyme (ACE) inhibitors may be responsible for gynecomastia, a hormonal influence also seems possible.⁸¹ The older cardiovascular drugs have important effects on the central nervous system, for example methyldopa influencing central alpha-2 activity.⁶ Erectile disorders caused by diuretics have been reported, the mechanism is unknown. Digoxin-associated impotence has recently been studied extensively and the underlying mechanism was shown to be inhibition of the Na/Ka-ATPase pump.⁸² The authors even remarked that digoxin might prove useful to inhibit erectile activity, for example after penile surgery.

In only a few comparative studies of different bloodpressure lowering regimes sexual function has been evaluated. In a trial with 626 men in need of antihypertensive treatment, 44% had a complaint on sexual functioning at the start of the trial. Half of these complaints concerned erectile function. The group on the ACE inhibitor captopril had as many patients improving as deteriorating (18%), while the patients on the beta adrenoceptor blocker propranolol and the patients on methyldopa improved in 9% and worsened in 25%. Of the patients who needed additional diuretics later in the trial, the patients on propranolol and a diuretic had extra problems with erectile function.⁸³ A comparison between a diuretic (hydrochlorothiazide) and an alpha adrenoceptor blocker (prazosin) showed that nocturnal erections were more rigid after the use of the alpha adrenoceptor blocker.⁸⁴ In a comparison of chlorthalidone, acebutolol, doxazosin, amlodipine, enalapril and placebo for hypertension treatment, pre-existing problems with erectile function improved with all patients on doxazosin (an alpha blocking agent).⁸⁵ Often cardiovascular drugs have a negative effect on erectile function, but disease related problems and drug related problems are hard to distinguish in the clinical setting. Any cardiovascular drug may cause erectile dysfunction. ACE inhibitors, calcium channel blockers and alpha blockers should be consid-

ered as alternatives in case of drug induced impotence.⁷⁴

Miscellaneous drugs

Histamine H₂-antagonists (used to lower gastric acid secretion) are related to impotence. H₁, H₂ and H₃ receptors have been found in the corpus cavernosum and stimulation leads to contraction of the smooth muscle cells.⁸⁶ H₂ receptors are not considered functionally important in the corpora and H₂-antagonists applied i.c. have no effect on erectile function.⁸⁶ Therefore the explanation of erectile dysfunction due to H₂-antagonists is probably their anti-androgenic effect.⁸⁷ Since these drugs are in the top-ten of prescription drugs the problem is relevant in spite of the probably low frequency in which it becomes manifest. Cimetidine was the first drug from this class associated with impotence, but there is no reason to assume the other H₂-antagonists are free of this problem.^{8,88} When it occurs, the medication must be changed to a completely different class of drugs, for example antacids.

Analgesics of the nonsteroid anti-inflammatory type (NSAID) are consistently reported as responsible for erectile dysfunction.^{7,8} Several prostanoids are synthesized in the corpus cavernosum and they have various effects on the smooth muscle.⁸⁹ This may explain the negative effects of some NSAIDs. In practice the problem is not frequently seen, taking into account that these drugs are taken very often.

Anti-androgens, prescribed for prostate cancer, will commonly lead to impotence. This effect is related to lowering testosterone to castration level which is caused by LHRH-agonists and by steroidal antiandrogens. When the patient cannot accept this side effect, it is possible to treat them with nonsteroidal antiandrogens, or treat them intermittently.⁹⁰⁻⁹² Whether these approaches are oncologically safe, has still to be established. Finasteride, a drug that blocks the conversion of testosterone into dihydrotestosterone and is used for symptomatic benign prostate hyperplasia, has caused impotence in 3.7% of the cases.⁹³ Recently some doubt is cast on the notion that dihydrotestosterone is not necessary for erectile function.¹⁹

Drugs to treat impotence

Extensive reviews, for oral medication and for drugs for i.c. use, were published in this journal.^{32,94} The alpha-2 adrenoceptor yohimbine has been used for its libido enhancing and its erection improving properties. The main pharmacological property is

alpha-blockade. In a double blind study good responses were noted in 21 and 13.8% for 6mg yohimbine three times daily and placebo.⁹⁵ This type of study is necessary before any claim can be made for this indication. Alpha-2 adrenoceptor blockade as such is insufficient for impotence treatment. Recently a study with more than 300 patients using placebo or delequamine orally was stopped because no benefits could be proven.⁹⁶ Alpha₂-blockade may be rational only in the younger age group with 'pure' psychogenic impotence.⁹⁷

The combination of central effects on the serotinine system combined with peripheral alpha adrenoceptor blocking properties as is seen in trazodone, has been advocated for oral impotence treatment.⁹⁸ In a double blind placebo controlled trial we were unable to detect any beneficial effect beyond the placebo effect.⁹⁹ Combining drugs may give synergistic effects. The combination of 50mg trazodon with 15mg yohimbine has recently been reported useful in a group of patients without physical abnormalities detectable. The responders had suffered impotence for a significant shorter period before treatment was started (6 vs 18 months).¹⁰⁰

Apomorphine, a dopamine agonist, can induce erections in patients who have no organic problems, but it has many side effects.¹⁰¹ The opiate antagonist naltrexone has been tried on idiopathic impotence patients, with positive effects only on the self-reported early-morning erections.¹⁰² Presently trials are conducted with drugs that have their rationale in the new insight in corpus cavernosum physiology. The nitric oxide precursor L-arginine has been tested, however the preliminary favorable data need confirmation.⁵⁷ A trial with oral medication that inhibits type V cGMP-specific phosphodiesterase, UK-92,480 (sildenafil), showed favourable results in impotence patients with no known organic cause.^{53,54}

Guidelines for clinical practice

It would be ideal to obtain information on the sexual function of any patient before medication is prescribed. Once the patient has been asked about it, he knows his doctor is interested and the issue can be discussed in the future. When the patient complains about impotence after exposure to a drug, first of all the exact nature of the complaint must be established. Ejaculation disorders must be differentiated from erectile failure. (Ejaculation disorders are also frequently drug related.) The time relationship between the start of the medication and the start of the complaint must be established. When the drug is known to be related to erectile disorders, see Table 1, an alternative drug may be tried. Suggestions are given in the earlier sections. When the drug is not known to cause impotence, detailed follow-up after

Table 1 Medication that is associated in the literature with erectile dysfunction. Based on Reactions (Weekly) January 1991 to January 1996 and References 8, 104 and 105.

acebutolol	clonazepam	guanethidine	metronidazole
acetazolamide	clonidine	guanfacine	metyrosine
alimemazine	clopenthixol	guanidine	mexiletine
allopurinol	clozapem	guanoclor	midazolam
alprazolam	cortisol	guanoxan	minoxidil
alprenolol	cortisone acetate	haloperidol	moclobemide
alseroxyon	cyclobarbitol	hexamethonium	morphine
alufibrate	cyclobenzaprine	homatropine	nadolol
amiloride	cyclosporin A	hydantoins	naltrexone
amiodarone	cyproterone	hydralazine	naprofen
amitriptyline	dantrolene	hydrochlorothiazide	nifedipine
amoxapine	deserpidine	hydrocortisone	nitrazepam
amphetamine	desipramine	hydromorphone	nitrendipine
anisotropine	desmethylinipramin	hydroxychloroquine	nizatidine
atenolol	dexamethasone	hydroxyprogesterone	nordazepam
atropine	dextroamphetamine	hydroxyzine	norethandrolone
aurothioglucose	dextromoramide	hyoscyamine	norethindrone
azathioprine	dextropropoxyphene	imipramine	norlutin
baclofen	diazepam	indapamide	nortriptyline
bendroflumethiazide	dibenzepine	indometacin	omeprazole
benperidol	dichlorphenamide	interferon	opipramol
benzatropine	diclofenac	iodide	orphenadrine
benzbromarone	dicyclomine	iproniazid	oxazepam
benzhexol	diethylpropion	isocarboxazid	oxazolam
benzphetamine	diphenhydramine	isoniazid	oxprenolol
benztropine	digoxin	isopropamide	oxybutynin
betamethasone	dihydralazine	itraconazole	oxycodone
betaxolol	dihydroergotamine	ketamine	oxymetazoline
bethanidine	dimenhydrinate	ketanserin	oxypertine
bezafibrate	disopyramide	ketazolam	oxyphenyclimine
biperiden	disulfiram	ketoconazole	oxyphenonium
bisoprolol	dixyrazine	labetalol	paramethasone
bopindolol	dosulepin	leuporelin	pargyline
bornaprine	doxepin	levomepromazine	paroxetine
bromazepam	doxylamine	lisinopril	penbutolol
bromocryptine	droperidol	lithium	pentazocine
bromperidol	ephedrine	lofepramine	pentobarbital
brotizolam	enalapril	lorazepam	perazine
bumetanide	ergotamine	lormetazepam	perhexiline
bunitrolol	estrogens	loxapine	pericyazine
bupranolol	ethionamide	maprotiline	perphenazine
buprenorphine	etofibrate	mazindol	pethidine
buserelin	famotidine	mebanazine	phencyclidine
buspirone	felodipine	mecamylamine	phendimetrazine
busulphan	fenfluramine	medroxyprogesterone	phenelzine
butaperazine	fenofibrate	melperon	phenmetrazine
butobarbital	finasteride	mepenzolate	phenobarbital
butizide	flecainide	mepindolol	phenoxymetazoline
camazepam	fluanisone	meprobamate	phenylephrine
camylofin	fluphenazine	mesoridazine	phenytolone
canrenoate-K	flunarizine	mesterolone	phentermine
captopril	flunitrazepam	metaclazepam	phenylpropanolamine
carazolol	fluocortolone	methadilazin	pimozide
carbamazepine	fluoxetine	methadone	pindolol
carteolol	flupentixol	methamphetamine	pipamperone
celiprolol	flurazepam	methanteline	pipoxolan
chlorprothixen	fluspirilene	methaqualone	pirenzepine
chlordiazepoxide	flutamide	methazolamide	piritramide
chloroquine	fluvoxamine	methotrexate	pizotifen
chlorpromazine	gemfibrozil	methyl dopa	poldine
chlortalidone	gestagenen	methylphenobarbital	polythiazide
chlorphentermine	gestonon caproate	methylprednisolone	pramiverine
choline theofyllinate	glutethimide	methyltestosterone	prazepam
cimetidine	glycopyrrolat	methysergide	prazosin
cinnarizine	glycopyrronium bromide	metipranolol	prednisolone
clobazam	goserelin	metixene	prednisone
clofibrate	guanabenz	metoclopramide	prednylidene
clomipramine	guanadrel	metoprolol	pridinol

(continued)

Table 1 (continued)

primidone	pseudoephedrine	terazosin	tridihexethyl
probutol	ramipril	testosterone	trifluoperazine
prochlorperazine	ranitidine	thiabendazole	trifluoperidol
procyclidine	rauwolfia	thiazinamium	triflupromazine
progesterone	reserpine	thiethylperazine	trihexyphenidyl
proguanil	scopolamine	thioridazine	trimeprazine
proloniumiodide	secobarbital	thiothixene	trimetaphan
promazine	selegiline	thiotixene	trimipramine
promethazine	simvastatin	tilidine	triptorelin
propafenone	sotalol	timolol	trospium chloride
propanolol	spironolactone	tranlycypromine	verapamil
propantheline	stilbestrol	trazodone	vincristine
prothipendyl	sulpiride	triamcinolone	vinylbital
protionamide	tamoxifen	triazolam	zopiclone
protriptyline	temazepam	trichlormethiazide	zuclopenthixol

dechallenge is recommended. When erectile function is restored in a reasonable period of time, then a rechallenge should be considered and the case may be reported. Priapism is easy to diagnose. The problem must be treated within 8 h.¹⁰³ Delay may impair future erectile function of the patient and may have legal sequelae. In these cases the alpha adrenoceptor blocking properties of future medication must be considered, especially with psychotropic pharmaca, cardiovascular drugs and medication for urinary outflow obstruction.

Acknowledgement

Professor W Lammers is gratefully acknowledged for his valuable suggestions.

References

- Kaplan HS. The concept of presbyrectia. *Int J Impot Res* 1989; 1: 59–65.
- Abouseif SR et al. The effect of venous incompetence and arterial insufficiency on erectile function: an animal model. *J Urol* 1990; 144: 790–793.
- Deamer RL, Thompson JF. The role of medications in geriatric sexual function. *Clin Geriatric Med* 1991; 7: 95–111.
- Slag MF et al. Impotence in medical outpatients. *JAMA* 1983; 249: 1736–1740.
- Curb JD et al. Long-term surveillance for adverse effects of antihypertensive drugs. *JAMA* 1985; 253: 3263–3268.
- Wein AJ, Aisdalen KN. Drug-induced male sexual dysfunction. *Urol Clin N Am* 1988; 15: 23–31.
- Lundberg PO, Biriell C. Impotence—the drug risk factor. *Int J Impot Res* 1993; 5: 237–239.
- Meinhardt W, Ottervanger JP, Lycklama á Nijeholt AAB, Zwartendijk J. Erectile dysfunction and priapism caused by prescription drugs. (in Dutch). *Ned Tijdschr Geneesk* 1995; 139: 1871–1873.
- Andersson K-E, Wagner G. Physiology of penile erection. *Physiol Rev* 1995; 75: 191–235.

- Rajfer J et al. Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission. *New Eng J Med* 1992; 326: 90–94.
- Burnett AL et al. Nitric oxide: a physiologic mediator of penile erection. *Science* 1992; 257: 401–403.
- Shafik A. Response of the urethral and intracorporeal pressures to cavernosus muscle stimulation: role of the muscles in erection and ejaculation. *Urology* 1995; 46: 85–88.
- Christ GJ, Lerner SE, Kim C, Melman A. Endothelin-1 as a putative modulator of erectile dysfunction: 1. Characteristics of contraction of isolated corporal tissue strips. *J Urol* 1995; 153: 1998–2003.
- Bancroft J, Wu FCW. Changes in erectile responsiveness during androgen replacement therapy. *Arch Sex Behav* 1983; 12: 59–66.
- Kwan M et al. The nature of androgen action on male sexuality: a combined laboratory self report study on hypogonadal men. *J Clin Endocrinol Metab* 1983; 57: 557–562.
- Nonomura K et al. Androgen binding activity in the spongy tissue of mammalian penis. *J Urol* 1990; 144: 152–155.
- Pickard R, Davenport A, Powell P. Lack of corpus cavernosum nitric oxide synthase immunoreactivity in men undergoing gender reassignment. *Int J Impot Res* 1995; 7 (suppl 1): 18 (abstract).
- Zvara P et al. Nitric oxide mediated erectile activity is a testosterone dependent event: a rat erection model. *Int J Impot Res* 1995; 7: 209–220.
- Lugg JA, Rajfer J, Gonzalez-Cadavid NF. Dihydrotestosterone is the active androgen in the maintenance of nitric oxide-mediated penile erection in the rat. *Endocrinology* 1995; 136: 1495–1501.
- Holmquist F, Persson K, Bødker A, Andersson K-E. Some pre- and postjunctional effects of castration in rabbit isolated corpus cavernosum and urethra. *J Urol* 1994; 152: 1101–1106.
- Leonard MP, Nickel CJ, Morales A. Hyperprolactinemia and impotence: why, when and how to investigate. *J Urol* 1989; 142: 992–994.
- Rosen RC, Kostis JB, Jekelis AW. Beta-blocker effects on sexual function in normal males. *Arch Sex Behav* 1988; 17: 241–255.
- Corvol P et al. Effets sexuels secondaires des spironolactones. Mécanismes possibles de l'action antiandrogène. *Nouv Presse Méd* 1976; 5: 619–624.
- Neri A, Aygen M, Zukerman Z, Bahary C. Subjective assessment of sexual dysfunction on long term administration of digoxin. *Arch Sex Behav* 1980; 9: 343–347.
- Meston CM, Gorzalka BB. Psychoactive drugs and human sexual behavior: the role of serotonergic activity. *J Psychoactive Drugs* 1992; 24 (1): 1–40.
- Jenck F et al. Evidence for a role of 5-HT_{1C} receptors in the

- antiserotonergic properties of some antidepressant drugs. *Eur J Pharmacol* 1993; 231: 223–229.
- 27 Paick J-S, Won Lee S. The neural mechanism of apomorphine-induced erection: an experimental study by comparison with electrostimulation-induced erection in the rat model. *J Urol* 1994; 152: 2125–2128.
- 28 Heaton JPW, Varrin SJ. Effects of castration and exogenous testosterone supplementation in an animal model of penile erection. *J Urol* 1994; 151: 797–800.
- 29 Rang HP, Dale MM, Ritter JM. *Pharmacology*, third edition. Churchill Livingstone: Edinburgh, 1995.
- 30 Kurt U et al. The efficacy of anti-serotonergic agents in the treatment of erectile dysfunction. *J Urol* 1994; 152: 407–409.
- 31 Haensel SM, Mos J, Schoot vd P, Slob AK. Testosterone is required for the stimulatory effects of 8-OH-DPAT on sexual behavior in castrated male rats. *Eur J Pharmacol* 1993; 233: 187–192.
- 32 Anderson K-E, Holmquist F, Wagner G. Pharmacology of drugs used for treatment of erectile dysfunction and priapism. *Int J Impot Res* 1991; 3: 155–172.
- 33 Fabbri A et al. Neuroendocrine control of male reproductive function: the opioid system as a model of control at multiple sites. *J Steroid Biochem* 1989; 32: 145–150.
- 34 Levin RM, Hypolite JA, Broderick GA. Metabolic responses of rabbit corpus cavernosum tissue to various forms of stimulation. *Int J Impot Res* 1995; 7: 187–194.
- 35 Jüneman KP et al. Neurophysiological aspects of penile erection: the role of the sympathetic system. *Br J Urol* 1989; 64: 84–92.
- 36 Dhabuwala CB, Ramakrishna CV, Anderson GF. Beta adrenergic receptors in human cavernous tissue. *J Urol* ; 133: 721–723.
- 37 Brindley GS. Cavernosal alpha-blockade: a new technique for investigation and treating erectile impotence. *Br J Psychiatry* 1983; 143: 332–337.
- 38 Baños JE, Bosch F, Farré M. Drug-induced priapism. Its aetiology, incidence and treatment. *Med Toxicol* 1989; 4: 46–58.
- 39 Walsh PC, Donker PJ. Impotence following radical prostatectomy: insight in etiology and prevention. *J Urol* 1982; 128: 492–497.
- 40 Krane RJ, Goldstein I, Saenz de Tajada I. Impotence. *New Eng J Med* 1989; 321: 1648–1659.
- 41 Goldstein I. Comment on Pharmacotherapy of impotence: where are we going? In: Lue TF (ed). *World Book of Impotence*. Smith-Gordon: London, 1992, pp 194–197.
- 42 Wespes E, Schulman C. Venous impotence: pathophysiology, diagnosis and treatment. *J Urol* 1993; 149: 1238–1245.
- 43 Holmquist F, Andersson K-E, Fovaeus M, Hedlund H. K-channel openers for relaxation of isolated penile erection tissues from rabbit. *J Urol* 1990; 144: 146–151.
- 44 Fan SF, Brink PR, Melman A, Christ GJ. An analysis of the maxi-K (K_{Ca}) Channel in cultured human corporal smooth muscle cells. *J Urol* 1995; 153: 818–825.
- 45 Christ GJ, Brink PR, Melman A, Spray DC. The role of gap junctions and ion channels in the modulation of electrical and chemical signals in human corpus cavernosum smooth muscle. *Int J Impot Res* 1993; 5: 77–96.
- 46 Ehmke H, Jünemann K-P, Mayer B, Kummer W. Nitric oxide synthase and vasoactive intestinal polypeptide colocalization in neurons innervating the human penile circulation. *Int J Impot Res* 1995; 7: 147–156.
- 47 Kim YC et al. Modulation of vasoactive intestinal polypeptide (VIP)—mediated relaxation by nitric oxide and prostanooids in the rabbit corpus cavernosum. *J Urol* 1995; 153: 807–810.
- 48 Burnett AL et al. Immunohistochemical localization of nitric oxide synthase in the autonomic innervation of the human penis. *J Urol* 1993; 150: 73–76.
- 49 Pickard RS, Powell PH, Zar MA. Nitric oxide and cyclic GMP formation following relaxant nerve stimulation in isolated human corpus cavernosum. *Br J Urol* 1995; 75: 516–522.
- 50 Schmidt P et al. Mechanisms of NO-induced relaxation of rabbit corpus cavernosum smooth muscle. *Int J Imp Res* 1995; 7: (Suppl 1): 12.
- 51 Andersson K-E, Holmquist F. Mechanisms for contraction and relaxation of human penile smooth muscle. *Int J Impot Res* 1990; 2: 209–225.
- 52 Sparwasser C, Drescher P, Will JA, Madson PO. Smooth muscle tone regulation in rabbit cavernosal and spongiosal tissue by cyclic AMP- and GMP-dependant mechanisms. *J Urol* 1994; 152: 2159–2163.
- 53 Eardley I et al. UK-92,480, a new oral therapy for erectile dysfunction, a double-blind, placebo controlled trial with treatment taken as required. *J Urol* 1996; 155 (suppl): 495A.
- 54 Gingell CJC et al. UK-92,480, a new oral treatment for erectile dysfunction: a double-blind, placebo controlled, once daily dose response study. *J Urol* 1996; 155 (suppl): 495A.
- 55 Stief CG et al. Preliminary results with the nitric oxide donor linsidomine chlorhydrate in the treatment of human erectile dysfunction. *J Urol* 1992; 148: 1437–1440.
- 56 Djamilian M, Stief CJ, Kuczyk M, Jonas U. Followup results of calcitonin gene related peptide and prostaglandins E1 in the treatment of erectile dysfunction. *J Urol* 1993; 149: 1296–1298.
- 57 Zorogniotti AW, Lizza EF. Effect of large doses of the nitric oxide precursor, L-arginine, on erectile dysfunction. *Int J Impot Res* 1994; 6 (1): 33–37.
- 58 Pollack MH, Reiter S, Hammerness P. Genitourinary and sexual adverse effects of psychotropic medication. *Int J Psychiatry Med* 1992; 22 (4): 305–327.
- 59 Ghadirian AM, Annable L, Bélanger MC. Lithium, benzodiazepines and sexual function in bipolar patients. *Am J Psychiatry* 1992; 149: 801–805.
- 60 Thompson JW, Ware MR, Blashfield RK. Psychotropic medication and priapism: a comprehensive review. *J Clin Psychiatry* 1990; 51: 430–433.
- 61 Azadzoi KM, Payton T, Krane RJ, Goldstein I. Effects of intracavernosal trazodone hydrochloride: animal and human studies. *J Urol* 1990; 144: 1277–1282.
- 62 Gartrell N. Increased libido in women receiving trazodone. *Am J Psychiatry* 1986; 143: 781–782.
- 63 Sullivan G. Increased libido in three men treated with trazodone. *J Clin Psychiatry* 1988; 49: 202–203.
- 64 Haensel SM, Rowland DL, Slob AK. Serotonergic drugs and masculine sexual behavior in laboratory rats and men. In: Bancroft J (ed). *The Pharmacology of Sexual Function and Dysfunction*. Elsevier Science, BV, 1995.
- 65 Smit DM, Levitte SS. Association of fluoxetine and the return of sexual potency in three elderly men. *J Clin Psychiatry* 1993; 54: 317–319.
- 66 Graziottin A et al. Fluoxetine and sexual counseling for premature ejaculation. *Int J Impot Res* 1995; 7 (suppl 1): 80 (abstract).
- 67 Lakin MM, Montague DK. Nonsurgical therapeutic alternatives for impotence. In: Hashmat AI, Das S (eds). *The Penis*. Lea and Febiger: Philadelphia, 1993, pp 154–173.
- 68 Hyttel H, Larssen JJ, Christensen V, Arnt J. Receptor binding profiles of neuroleptics. In: Hoes MJAJM, Kleyn vd A, Nijdam (eds). *Criteria for Choice of Psychotropics*. Eisma BV: Leeuwarden, 1986, pp 46–51.
- 69 Hemert v AM, Meinhardt W, Moehadjir D, Kropman RF. Recurrent priapism as a side-effect of zuclopenthixol decanoate. *Int Clin Psychopharmacology* 1995; 10: 199–200.
- 70 Persson C et al. Correlation of altered penile ultrastructure with clinical arterial evaluation. *J Urol* 1989; 142: 1462–1467.
- 71 Kim JH et al. Experimental hypercholesterolemia in rabbits induces cavernosal atherosclerosis with endothelial and smooth muscle cell dysfunction. *J Urol* 1994; 151: 198–205.
- 72 Smith PJ, Talbert RL. Sexual dysfunction with antihypertensive and antipsychotic agents. *Clin Pharmacol* 1986; 5: 373–384.
- 73 Hsieh JT, Muller SC, Lue TF. The influence of blood flow and blood pressure on penile erection. *Int J Impot Res* 1989; 1: 35–42.
- 74 Weiss RJ. Effects of antihypertensive agents on sexual function. *Amer Fam Phys* 1991; 44: 2075–2082.



- 75 Kerfoot WW *et al.* Comparative efficacy of calcium channel blocker activity on isolated rabbit corpus cavernosum. *Int J Impot Res* 1992; 4: 1–8.
- 76 Brindley GS. Pilot experiments on the actions of drugs injected into the corpus cavernosum penis. *Br J Pharmacol* 1986; 87: 495–500.
- 77 Thuillez C *et al.* Arterial vasodilating profile and biological effects of pinacidil in healthy volunteers. *Br J Clin Pharmacol* 1991; 31: 33–39.
- 78 Andersson K-E. Clinical Pharmacology of potassium channel openers. *Pharmacol Toxicol* 1992; 70: 244–254.
- 79 Giraldi A, Wagner G. Effects of pinadil upon penile erectile tissue, in vitro and in vivo. *Pharmacol Toxicol* 1990; 67: 235–238.
- 80 Cavallini G. Minoxidil versus nitroglycerine: a prospective, double-blind, controlled trial in transcutaneous therapy for organic impotence. *Int J Impot Res* 1994; 6 (4): 205–212.
- 81 Meyboom RHB, Assies J, Bemt vd PMLA, Konig d GHP. Galactorroea and gynaecomastia as side effect of drugs. (in Dutch). *Ned Tijdschr Geneesk* 1993; 137: 2498–2503.
- 82 Gupta S *et al.* A new mechanism for digoxin-associated impotence: in vitro and in vivo study. *J Urol* 1996; 155: 621A.
- 83 Croog SH *et al.* Sexual symptoms in hypertensive patients. A clinical trial of antihypertensive medications. *Arch Intern Med* 1988; 148: 788–794.
- 84 Scharf MB, Mayleben DW. Comparative effects of prazosin and hydrochlorthiazide on sexual function in hypertensive men. *Am J Med* 1989; 86 (suppl 1B): 110–112.
- 85 Grimm RH jr, Grandits G, Svendsen K. Sexual problems and antihypertensive drug treatment: results of the treatment of mild hypertension study (TOMHS). *J Urol* 1996; 155: 469A.
- 86 Kim YC, Davies MG, Lee TH, Hagen P-O, Carson CC. Characterization and function of histamine receptors in corpus cavernosum. *J Urol* 1995; 153: 506–510.
- 87 Galbraith RA, Michnovicz JJ. The effect of cimetidine on the oxidative metabolism of estradiol. *N Engl J Med* 1989; 321: 269–274.
- 88 Lundberg PO, Biriell C. Sexual dysfunction as a suspected drug reaction reported to WHO collaborating centre for international drug monitoring. *Therapie* 1993; 48: 457–459.
- 89 Schrör K. Erectile dysfunction—vasomotor actions of PGE₁, its metabolites and other prostaglandins. *Adv Prostaglandin Tromboxane Leuko Res* 1995; 23: 533–538.
- 90 Migliari R, Muscas G, Usai F. Effect of casodex on sleep-related erections in patients with advanced prostate cancer. *J Urol* 1992; 148: 338–341.
- 91 Kaisary AV, Tyrell CJ, Beacock C, Lunglmayr G, Debruyne F and the Casodex study group. A randomised comparison of monotherapy with Casodex 50mg and castration in the treatment of metastatic prostate carcinoma. *Eur Urol* 1995; 28: 215–222.
- 92 Akakura K *et al.* Effects of intermittent androgen suppression on androgen-dependent tumours: Apoptosis and serum prostate-specific antigen. *Cancer* 1993; 71: 2782–2790.
- 93 Stoner E and members of the finasteride study group. Three years of safety and efficacy data on the use of finasteride in the treatment of benign prostate hyperplasia. *Urology* 1994; 43: 284–294.
- 94 Jünemann KP, Alken P. Pharmacotherapy of erectile dysfunction: a review. *Int J Impot Res* 1989; 1: 71–93.
- 95 Morales A *et al.* Oral and transcutaneous pharmacologic agents in the treatment of impotence. *Urol Clin N Amer* 1988; 15: 87–93.
- 96 Meuleman EJH. personal communication.
- 97 Munoz M, Bancroft J, Beard M. Evaluating the effects of an alpha-2 adrenoceptor antagonist on erectile function in the human male. *Psychopharmacology* 1994; 115: 471–477.
- 98 Lance RL, Albo M, Costabile RA, Steers WD. Oral trazodone as empirical therapy for erectile dysfunction: a retrospective review. *Urology* 1995; 46: 117–120.
- 99 Meinhardt W *et al.* Trazodone versus placebo for erectile dysfunction, a doubleblind multicentre trial. *Int J Imp Res* (submitted).
- 100 Montorsi F *et al.* Effect of yohimbine-trazodone on psychogenic impotence: a randomized double-blind, placebo-controlled study. *Urology* 1994; 44: 732–736.
- 101 Heaton JPW *et al.* Recovery of erectile function by the oral administration of apomorphine. *Urology* 1995; 45: 200–206.
- 102 Ahlen VH *et al.* Opiate antagonists in erectile dysfunction: a possible new treatment option?. *Eur Urol* 1995; 28: 246–250.
- 103 Porset H, Ahlen H van. Pharmakon-induzierte Priapismen—Ein Erfahrungsbericht über 101 Fälle. *Urologe (A)* 1989; 28: 84–87.
- 104 Moors Mommers MCT. Influence of medical and recreational drugs on sexual functions. (In Dutch). *Geneesmiddelen-bulletin* 1994; 28: 53–56.
- 105 Roth S, Semjonow A, Rathert P. *Klinische Urologie, vom Befund zur Therapie*. Springer-Verlag: Berlin, 1993.